Latest From Akorn Inc.
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
US generics company Akorn, which has been struggling since Germany’s Fresenius walked away from a $4.3bn merger three years ago, plans to put itself up for sale under an extended standstill agreement with lenders.
Injectable bacitracin, often used as a surgical irrigant, carries serious risks of nephrotoxicity and anaphylaxis; product is no longer prescribed for its lone approved indication in pediatric pneumonia. FDA’s decision aligns with advisory committee recommendations in 1984 and 2019.
- Medical Devices
- Generic Drugs
- OTC, Consumer
- Radiopharmaceuticals, Contrast Agents
- Specialty Pharmaceuticals
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Akorn Inc.
- Senior Management
Raj Rai, CEO
Duane A Portwood, CFO
Jonathan Kafer, EVP, Sales & Mktg.
Bruce Kutinsky, PharmD, COO
Steve Lichter, EVP, Pharma Ops
Randall E Pollard, Chief Accounting Officer
- Contact Info
Phone: (800) 932-5676
1925 West Field Ct.
Lake Forest, IL 60045
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.